French Trial Tragedy: Experts Recommend Tighter Phase I Rules
This article was originally published in Scrip
Executive Summary
The French committee investigating the data behind the Phase I study of Bial's FAAH inhibitor BIA 10-2474, which resulted in the death of one volunteer and the hospitalization of five others in January 2016, has made a number of recommendations for tightening up the regulations on first-in-human studies.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.